Halozyme Therapeutics, Inc. Free Cash Flow 2009–2025
Halozyme Therapeutics, Inc. reported $644.59M of free cash flow for fiscal 2025. That was 37.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +1117.4%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $644.59M | +37.6% |
| FY 2024 | $468.37M | +25.5% |
| FY 2023 | $373.28M | +58.6% |
| FY 2022 | $235.30M | -21.0% |
| FY 2021 | $297.98M | +462.8% |
| FY 2020 | $52.95M | +159.2% |
| FY 2019 | $-89.46M | -65.2% |
| FY 2018 | $-54.16M | -140.8% |
| FY 2017 | $132.70M | +348.0% |
| FY 2016 | $-53.52M | -35.7% |
| FY 2015 | $-39.44M | +19.3% |
| FY 2014 | $-48.89M | +5.3% |
| FY 2013 | $-51.64M | +21.4% |
| FY 2012 | $-65.69M | -87.0% |
| FY 2011 | $-35.13M | +23.7% |
| FY 2010 | $-46.03M | -10.6% |
| FY 2009 | $-41.61M | — |
Source: Halozyme Therapeutics, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported $644.59M of free cash flow for fiscal 2025. That was 37.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +1117.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s free cash flow?
Halozyme Therapeutics, Inc. (HALO) reported free cash flow of $644.59M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.